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doi:10.101Reduced-Intensity Conditioning Regimens
for Allogeneic Transplantation in Children with Acute
Lymphoblastic Leukemia
Michael R. Verneris,1 Mary Eapen,2 Reggie Duerst,3 Paul A. Carpenter,4 Michael J. Burke,1
B. V. Afanasyev,5 Morton J. Cowan,6 Wensheng He,2 Robert Krance,7 Chi-Kong Li,8
Poh-Lin Tan,9 John E. Wagner,1 Stella M. Davies10Reduced-intensity conditioning regimens have been used extensively in adults with hematologic malignancies.
To address whether this is a feasible approach for children with acute lymphoblastic leukemia, we evaluated
transplant outcomes in 38 recipients transplanted from 1995-2005 for whom this was their first transplant.
The median age at transplant was 12 years, and 47% had performance scores\90%. Disease status was first
complete remission (CR) in 13%, $CR2 in 60% of patients, and 22% had active disease at transplantation.
Matched related donors were available for a third of patients, about half of whom received bone marrow
(BM) and the others, peripheral blood progenitor cells. Sixty percent of unrelated donor transplant recipients
received peripheral blood progenitor cells. The day-100 probability of grade II-IV acute graft-versus-host dis-
easewas 37% and the 3-year probability of chronic graft-versus-host disease, 26%. At 3 years, the probability of
treatment-related mortality was 40%, relapse 37%, and disease-free survival 30%. These data indicate long-
term DFS can be achieved using reduced-intensity conditioning regimens in children with acute lymphoblastic
leukemia. Given the relatively small cohort, these findings must be validated in a larger population.
Biol Blood Marrow Transplant 16: 1237-1244 (2010) 2010 American Society for Blood and Marrow TransplantationKEY WORDS: Pediatric, ALL, Reduced-intensity conditioningINTRODUCTION
Acute lymphoblastic leukemia (ALL) is 1 of the
most commonly diagnosed pediatric malignancies. Us-
ing conventional chemotherapy, up to 80% of patients
are expected to achieve long-term hematologic remis-
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6/j.bbmt.2010.03.009pediatric population means that recurrent ALL remains
a common indication for allogeneic hematopoietic cell
transplantation (allo-HCT). Three-year disease-free
survival (DFS) for children transplanted in second com-
plete remission (CR) using myeloablative (MA) condi-
tioning and allo-HCT has been reported to be 30%
to 40%, with some studies reporting DFS as high as
70% [2]. In common with most transplant studies, treat-
ment failure is because of both treatment-related mor-
tality (TRM) and disease recurrence.
Over the past 10 years considerable experience has
been gained using reduced-intensity conditioning
(RIC) regimens for allo-HCT. Although a number of
different regimens have been tested, 1 unifying feature
is that they have the potential for acceptable rates of
donor engraftment and lower TRM relative to conven-
tional or dose-intensive MA conditioning. Because
most children tolerate conventional dose-intensive
conditioning and TRM increases with age, RIC has
mainly been reserved for older patients or those with
poor performance status.
One fundamental difference between RIC and
MA conditioning is the mechanism of disease control.
With MA conditioning, relapse protection is pro-
vided by the dose-intensive chemotherapy and/or
total body irradiation (TBI) and the allogeneic,1237
1238 Biol Blood Marrow Transplant 16:1237-1244, 2010M. R. Verneris et al.graft-versus-leukemia (GVL) effect. In contrast, the
lower dose of chemotherapy and/or irradiation
associated with RIC may provide little up-front disease
control, and thus, the efficacy of RIC has been ascribed
to the posttransplant GVL effect. Although GVL
reactions are difficult to document in real time, both
the kinetics of disease regrowth and responsiveness to
GVL have had bearing on patient selection for RIC.
Thus, RIC has been more commonly used in patients
with chronic leukemia and indolent lymphoma [3]. En-
thusiasm for using RIC for ALL has been appropriately
guarded, because of the poor responsiveness to post-
HCT immune-based approaches in ALL, including
rapid tapering of immune suppression and donor
lymphocyte infusion (DLI) following relapse [4,5].
Under certain circumstances, RIC may be indicated
for patients with ALL who require allo-HCT, but are
ineligible for a dose-intensive conditioning. Such
indications include: poor performance status, active
infections, significant organ dysfunction, or advanced
age. Transplant outcome data after various RIC regi-
mens for ALL are few and, with 1 exception, are limited
to reports in adults. To date, 6 reports have focused on
the outcomes of HCT with RIC for ALL [6-11],
whereas other reports have included patients with
ALL and other leukemias [12-14]. The report by
Pulsipher and colleagues [14] is the only 1 limited to
children, and only 17 of 47 patients in that report had
ALL. Thus, the effectiveness of RIC regimens for pedi-
atric ALL has not been extensively reported. Here, we
detail outcomes for children with ALL who received
RIC allo-HCT as their first transplant and reported
to the Center for International Blood and Marrow
Transplant Research (CIBMTR).METHODS
Data Collection
The CIBMTR is a voluntary working group of
more than 450 transplant centers worldwide that
contribute detailed data on consecutive allogeneic
and autologous transplants to a Statistical Center at
the Medical College of Wisconsin. Participating cen-
ters are required to report all consecutive transplants.
Data collected include disease type, age, sex, pretrans-
plant disease stage and chemotherapy responsiveness,
date of diagnosis, graft type, conditioning regimen,
posttransplant disease progression and survival, devel-
opment of a new malignancy, and cause of death. A
subset of the reported transplants are selected for
detailed reporting using a weighted randomization
scheme and include detailed disease, and pre- and
posttransplant clinical information. All subjects are
followed longitudinally, with yearly follow-up. Com-
puterized error checks, physicians’ review of submitted
data, and on-site audits of participating centers ensuredata quality and compliance. As stated before, there
has only been 1 other study to report outcomes of
for RIC in pediatric ALL (PBMTC ONC313) [14].
Based on a number of factors (participating centers,
conditioning regimen, date of transplant), only 1 pa-
tient (UPN #9) has potentially participated in that
trial. This study was approved by the institutional
review board of the Medical College of Wisconsin.
Endpoints
Neutrophil recovery was defined as achieving an
absolute neutrophil count (ANC) of $0.5  109/L
for 3 consecutive days and platelet recovery, $20 
109/L for 7 days, unsupported. Diagnoses of grades
II, III, and IV acute graft-versus-host disease
(aGVHD) and chronic GVHD (cGVHD) were based
on published criteria [15,16]. TRM was defined as
death in continuous CR and relapse, hematologic
leukemia recurrence. Treatment failure (inverse of
DFS) was defined as death from any cause or relapse.
Statistical Methods
The probability of neutrophil and platelet recovery,
aGVHD and cGVHD, TRM, and relapse were
calculated with the use of the cumulative-incidence-
function method [17]. For neutrophil and platelet recov-
ery and GVHD, death without the event (hematopoietic
recovery or GVHD) was the competing event. Data on
patients without an event were censored at last contact.
For TRM, relapse was the competing event and for
relapse, TRM, the competing event. Univariate proba-
bilities of DFS and overall survival (OS) were calculated
using the Kaplan-Meier estimator [17]. For DFS, death
or relapse were events, and patients alive and in remis-
sion were censored at last contact. For OS, death from
any cause was an event, and patients alive were censored
at last contact. All P-values are 2-sided, and analyses
were performed using SAS software, version 9.1 (SAS
Institute, Cary, NC).RESULTS
Patient Demographics
Table 1 shows the pretransplant characteristics of
the 38 patients aged#18 years with ALL who received
RIC allo-HCT as their first transplant. Transplanta-
tions occurred between 1995 and 2005. Most patients
(66%) were between the ages of 11 and 18 years.
Approximately one-half (47%) had performance scores
\90. Most patients were in second or subsequent CR at
HCT. For patients transplanted in CR2 or beyond
CR2, the median duration of CR1 was 32 (range:
6-89) months. Approximately 20% of patients had
active disease at time of HCT (either primary induction
failure [n5 1] or in relapse [n5 7]). The median follow-
up for surviving patients was 48 (range: 3-131) months.
Table 1. Patient, Disease, and Transplant Characteristics
Variables Number
Number of patients 38
Age, years
1-10 13
11-18 25
Recipient cytomegalovirus
seropositivity
20
Performance score
90-100 18
<90 19
Unknown 1
Disease status prior to transplant
1st complete remission 5
2nd complete remission 13
3rd complete remission 5
4th complete remission 5
Relapse/primary induction failure 8
Unknown 2
Conditioning regimen
Total-body irradiation + other agents 13
Busulfan + other agents 12
Cyclophosphamide + other agents 6
Melphalan + other agents 7
Type of donor
HLA-identical sibling 12
Matched related 1
Unrelated donor 25
GVHD prophylaxis
T cell depletion 2
Calcineurin inhibitor ± other agents 17
Calcineurin inhibitor + methotrexate 16
Methotrexate + other agents 1
Unknown 2
GVHD indicates graft-versus-host disease.
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There was an increase in the use of RIC during the
study period; approximately one-third of transplants in
the current analysis were performed from 1995 to 2000
and two-thirds, from 2001 to 2005. Thirteen patients
received allografts from matched related donors and
the remaining patients received allografts from unre-
lated donors (Tables 2 and 3). Regimens were consid-
ered RIC if the cumulative dose of busulfan was
\9 mg/kg, melphalan \150 mg/m2 or TBI #450
cGy, single fraction or 600 to 800 cGy, multiple frac-
tions [18]. Regimens that combined busulfan and mel-
phalan were considered to be MA. The decision to use
RIC for patients was at the discretion of the transplant
center and 10 of 38 patients were treated on institu-
tional protocols. None of the patients were reported
to have organ dysfunction (renal, cardiac, or pulmo-
nary) or a life-threatening infection immediately prior
to transplantation. GVHD prophylaxis varied, al-
though most patients received calcinuerin-inhibitor
containing GVHD prophylaxis (Table 1).Transplant-Associated Outcomes
All patients developed severe neutropenia (ANC$
0.5  109/L) after transplant conditioning, and 35 of
38 patients achieved neutrophil recovery. The day-28probability of neutrophil recovery was 82% (95%
confidence interval [CI] 67-92); 31 of 38 patients.
The remaining 4 patients remained neutropenic for
a longer period. The day-100 probability of platelet
recovery was 79% (95% CI 65-90). Twenty-four
patients with an ANC$0.5 109/L had chimerism as-
say performed. Donor engraftment (.90% donor de-
rived cells in the peripheral blood or marrow) was
observed in 21 patients (88%)\3 months after trans-
plant. Some patients (n 5 9) had serial chimerism as-
says performed as late as 2 years. The frequency and
timing of chimerism assay was at the discretion of
the transplant center. One patient received DLI and
another patient received a second transplant for treat-
ment of mixed chimerism without evidence of relapse.
For the patient who received DLI, this occurred 4
months after the first transplant and this patient died
7 months later of recurrent leukemia and the second
transplant recipient underwent this procedure 4
months after the first transplant and died 1 month later
from organ failure (Table 2).
In univariate analysis, the probability of TRM at
100 days and 3 years was 19% (95% CI 8%-33%) and
32% (95% CI 17%-49%), respectively (Figure 1A).
Sixteen patients developed grade II and 9 patients, grade
III-IV aGVHD (Tables 2 and 3). The day-100 proba-
bility of grade II-IV aGVHD was 37% (95% CI
22%-53%) and grade III-IV aGVHD, 24% (95% CI
12%-38%) (Figure 1B). The probability of grade II-
IV or III-IV aGVHD did not change significantly at
day-180. cGVHD occurred in 12 of 38 patients
(Tables 2 and 3). The 3-year probability of cGVHD
was 26% (95% CI 12%-42%), with the severity re-
ported as limited in 2 patients and extensive in 10
patients.
Leukemia relapse occurred in 14 patients post-
HCT; the 3-year probability of relapse was 38%
(95% CI 23%-55%) (Figure 1C). One patient received
a second HCT from a different unrelated donor and
5 patients, DLI. Twenty-three patients are dead: 14
from recurrent disease, and 9 from a treatment-related
complication (Table 2). Fifteen patients are alive at
last follow-up (Table 3). The 3-year probabilities of
DFS and OS were 30% (95% CI 15%-47%)
(Figure 1D) and 36% (95% CI 20%-53%), respectively.
Transplant outcomes according to performance
score at transplantation were evaluated, as none of
these patients were reported to have organ dysfunction
or a life-threatening infection just prior to initiation of
transplant conditioning. We did not observe statisti-
cally significant differences in TRM (39% versus
22%, P 5 .27) and DFS (28% versus 31%, P 5 .84)
in patients with performance scores\90 and 90-100,
respectively. The relatively small numbers of patients
may explain our inability to detect a significant differ-
ence despite an absolute difference of 17% for TRM.
We also examined for an effect of TBI-containing
Table 2. Characteristics of Patients Who Died of Leukemia Relapse or Transplant-Related Complication
Patient Age Performance Score Disease Status Donor/Graft Conditioning Regimen Acute GVHD Chronic GVHD Time to Death
Primary Cause
of Death
1 17 80 CR2 MSD, BM TBI (100 cGy) + Mel (136 mg/m2) grade 4 3 months GVHD
2 10 20 relapse MSD, BM Bu (5mg/kg) + Cy 1 month organ failure
3 2 90 relapse Unrelated, CB Cy + etoposide + ATG 1 month infection
4* 16 70 relapse MSD, PBPC TBI (450 cGy) + FLU + ATG 1.5 month relapse
5* 12 50 CR2 MSD, PBPC Cy + FLU + ATG 11 months relapse
6 3 40 unknown Unrelated, BM Cy + FLU 4 months relapse
7 7 90 CR2 Unrelated, PBPC FLU + Mel (140 mg/m2) + ATG grade 3 2 months GVHD
8 12 90 CR2 Unrelated, PBPC Bu (8 mg/kg)+ FLU + ATG extensive 7 months relapse
9 8 80 CR2 Unrelated, CB Bu (8 mg/kg) + FLU + ATG 18 months infection
10 6 80 relapse Unrelated, PBPC TBI (400 cGy) + Bu (6 mg/kg) + FLU grade 4 extensive 7 months GVHD
11 11 80 CR4 Unrelated, PBPC FLU + Mel (111 mg/m2) + ATG 2 months hemorrhage
12 14 80 Induction failure MSD, PBPC Bu (6 mg/kg) + etoposide + FLU + ATG grade 4 extensive 4 months GVHD
13* 16 100 CR2 MSD, BM TBI (600 cGy, frac) + Cy grade 2 extensive 11 months GVHD
14* 12 90 CR3 Unrelated, PBSC TBI (450 cGy)+ FLU + alemtuzumab 7 months relapse
15 13 100 CR3 Unrelated, PBPC FLU + Mel (120 mg/m2)+ thiotepa 7 months relapse
16 13 90 CR4 Unrelated, PBPC Bu (8 mg/kg) + FLU + ATG grade 2 extensive 30 months relapse
17 13 80 CR4 Unrelated, BM Bu (6 mg/kg) + FLU + ATG grade 2 extensive 25 months GVHD
18 15 100 CR2 Unrelated, PBPC Bu (6 mg/kg) + FLU + alemtuzumab grade 3 2 months GVHD
19* 15 80 CR1 Unrelated, CB TBI (600 cGy frac) + Cy + Mel (137 mg/m2) + ATG 4 months organ failure
20 18 80 CR4 Unrelated, PBPC FLU + Mel (100 mg/m2) + ATG grade 2 limited 43 months relapse
21* 17 70 CR4 Unrelated, PBPC FLU + Mel (130 mg/m2) + alemtuzumab grade 2 9 months relapse
22 13 100 CR2 Unrelated, BM TBI (600 cGy frac) + FLU + alemtuzumab 2 months relapse
23 17 100 CR2 Unrelated, PBPC Bu (7 mg/kg) + FLU grade 3 3 months GVHD
CR indicates complete remission; CB, cord blood; BM, bone marrow; DLI, donor lymphocyte infusion; RIC, reduced-intensity conditioning; HCT, hematopoietic cell transplantation; PBPC, peripheral blood pro-
genitor cells; MSD, matched sibling donor; TBI, total body irradiation; Frac, fractionated TBI dose; Bu, busulfan; Cy, cyclophosphamide; FLU, fludarabine; ATG, antithymocyte globulin; Mel, melphalan.
Intervention post-RIC HCTand outcome.
*Patient # 4: donor lymphocyte infusion (DLI) for leukemia relapse 1 month after RIC HCTand died 15 days after DLI.
*Patient #5: DLI for mixed chimerism 5 months after RIC HCTand died 2 months after DLI.
*Patient #13: DLI for leukemia relapse 6 months after RIC HCTand died 5 months after DLI.
*Patient #14: DLI for leukemia relapse 5 months after RIC HCTand died 2 months after DLI.
*Patient #19: Second allo-HCT (different donor) for mixed chimerism 3 months after RIC HCTand 1 month after second HCT. Conditioning regimen for second HCT is not known.
*Patient #21: DLI for leukemia relapse 8 month after RIC HCTand died 1 month after DLI.
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Biol Blood Marrow Transplant 16:1237-1244, 2010 1241RIC and Pediatric ALLregimens on DFS and found none (30% with TBI con-
taining versus 27% with non-TBI regimens, P 5 .85).DISCUSSION
In this report we describe the transplant outcomes
for children aged #18 years with ALL who received
RIC before their first allo-HSCT. We found that
RIC regimens were associated with myelosuppression
in all patients along with high rates of TRM and
aGVHD and cGVHD. Similarly, leukemia recurrence
was also high, resulting in modest DFS rates at 3 years.
Several patients reported herein had performance
scores of 70 or 80 (Karnofsky or Lansky scale) and/
or were in second or subsequent CR at HCT and
were thus at significant risk for transplant-related
complications and/or leukemia relapse.
An important limitation of this registry study is the
lack of information regarding the rationale for the
selection of RIC. We speculate patients who received
RIC were either treated on an institutional protocol
(26% of study population) or judged to be at high
risk for TRM by the treating physician based on inten-
sity of therapies received prior to HCT even though
none of the patients were reported to have renal, car-
diac, or pulmonary function dysfunction, poor perfor-
mance score, and/or more advanced disease status
(beyond second CR). There may also be several un-
measured factors that may have contributed to the se-
lection of RIC for allo-HCT in these children. In this
context, these data lend support to the notion that RIC
regimens can expand HCT options for children and
adolescents otherwise unsuitable for dose-intensive
MA conditioning who would succumb to their disease
with chemotherapeutic regimens alone.
One of the perceived benefits to RIC has been the
lower TRM relative to traditional dose-intensive
conditioning. We observed TRM rates (19% at day
100 and 32% at 3 years) consistent with other reports
describing outcomes for RIC with adult ALL, where
TRM ranged from 17% to 40% [6-11]. Moreover, in
these reports, there appears to be a trend for higher
TRM when patients with advanced disease or
chemotherapy refractory leukemia are included. The
high rate of TRM in our study sharply contrasts with
the only other large multicenter pediatric RIC study
were TRM was much lower (11%) [14]. This
difference might be explained by the use of a uniform
conditioning regimen in the report by Pulsipher and
colleagues [14], together with the fact that transplants
were carried out in a more contemporary era than this
analysis, which spanned over a decade. Interestingly,
Pulsipher and colleagues [14] report relapse rates of
43% at 2 years, which are higher than that observed
in the current analysis. This may in part be attributed
to the inclusion patients who had failed prior
Figure 1. (A) Probability of TRM. (B) Probabilities of grade II-IV and III-IV aGVHD. (C) Probability of leukemia relapse. (D) Probability of DFS.
1242 Biol Blood Marrow Transplant 16:1237-1244, 2010M. R. Verneris et al.transplantation and at higher risk for recurrent leuke-
mia compared to the population in this analysis. TRM
is the competing event for relapse and TRM is ex-
pected to be low when recurrence rate is high.
Although RIC regimens are commonly used for
adults with chronic leukemia and low to intermediate
grade lymphoma [3], a major concern with using
RIC regimens for pediatric ALL is the faster growth
kinetic of ALL that might result in higher relapse rates.
This concern is, perhaps, magnified by the fact that
RIC relies mainly on immunologic mechanisms for
eradication of disease (ie, GVL) and yet, post-HCT
adoptive immunotherapies designed to exploit GVL,
like DLIs or natural killer cells have been disappoint-
ing for treating relapsed ALL [4,19]. However, in the
current study, the relapse rate at 3 years was 38%,
which is comparable to that after dose-intensive MA
conditioning regimens in children with ALL [2], and
to that reported after RIC allo-HCT in adults with
ALL [6-8,10,11]. Most patients in the current
analysis were in second or subsequent CR or had
active disease at HCT, and despite the relatively high
relapse rate, one-third of the patients are alive and
disease free, which supports the notion that sustained
remission in ALL can also be achieved in children after
RIC and allo-HCT. Given the relatively small num-
bers of patients in the current analysis, these findings
must be validated in a larger series. Further, the
relatively small numbers of patients prevented us
from examining for an effect of aGVHD or cGVHD
on relapse in the current analysis. Nevertheless, a po-
tent effect of aGVHD in reducing relapse in children
with ALL receiving unrelated donor transplants after
dose-intensive MA conditioning has been reported,suggesting a role for immune-based mediation of re-
lapse risk [20]. Similarly, lower doses of immune sup-
pression (CsA) after transplantation have been
associated with relapse protection in ALL [21,22]. In
some studies adoptive transfer of donor lymphocytes
can reverse rising host chimerism associated with
minimal residual disease [23]. As well, an association
between cGVHD and sustained remission following
RIC and allo-HCT has been reported for ALL [11].
Taken together, these reports support the assertion
that ALL is sensitive to a GVL effect [24-26].
Despite the small numbers of patients and their
heterogeneity with respect to performance score,
disease status at HCT, and donor source, this is the
first report on the use of RIC regimens for pediatric
ALL. All children received RIC and allo-HCT as their
first transplant. The observed 3-year DFS rates are
comparable to those after dose-intensive MA condi-
tioning regimens and allo-HCT. Although our obser-
vations must be interpreted with caution, the modest
success reported herein offers a potentially life-saving
treatment option to children who may otherwise not
be eligible for allo-HCT. Only a clinical trial that
uses a uniform RIC regimen, GVHD prophylaxis,
and donor-graft source can further establish the role
of RIC allo-HCT for pediatric ALL.ACKNOWLEDGMENTS
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